Two late-breaking presentations focused on SABRIL vision data were presented today at the annual meeting of the American Epilepsy Society (AES). One presentation includes interim results from a prospective, open-label trial of retinal structure and function in adult patients with refractory complex partial seizures (CPS), and the other presents four-year data from Lundbeck’s SABRIL patient registry.1,2 Because of the risk of permanent vision loss, the U.S. Food and Drug Administration (FDA) requires a Risk Evaluation and Mitigation Strategy (REMS) for SABRIL which includes the ongoing registry.
Help employers find you! Check out all the jobs and post your resume.
